Fly News Breaks for January 17, 2019
FPRX
Jan 17, 2019 | 08:32 EDT
As previously reported, Wedbush analyst Robert Driscoll upgraded Five Prime to Outperform from Neutral, with a $16 price target, given recent declines, which he believes leaves a more favorable risk/reward ahead of multiple clinical catalysts this year, and as the company focuses efforts on clinical development of its broad pipeline. Although 2019 data readouts will be centered on earlier stage assets, the analyst sees increased investor enthusiasm for the company's broad clinical pipeline, ahead of potential readouts for late stage assets next year.
News For FPRX From the Last 2 Days
There are no results for your query FPRX